Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry

Table 2 Competing risk analysis of factors associated with IBTR

	SHR	95% CI	P value
Genetic testing criteria met^a	2.92	1.18–7.23	0.020
Age (years)
< 50	1.00	Ref
50–59	0.47	0.17–1.32	0.153
60–69	0.47	0.16–1.31	0.149
≥ 70	0.83	0.32–2.18	0.708
T stage group
pT1a and pT1b	1.00	Ref
pT1c and pT2	2.24	0.99–5.06	0.053
Molecular subtype
Luminal A-like	1.00	Ref
Luminal B-like	0.95	0.43–2.13	0.907
HER+	2.96	0.79–11.0	0.106
Triple negative	1.98	0.70–5.59	0.197
Multifocal breast cancer	3.97	1.36–11.5	0.011
Lymphovascular involvement	1.07	0.30–3.75	0.921
Perineural invasion	2.20	0.37–13.0	0.384

Bold was used to illustrate results with p-values below the significance cutoff of 0.05
^aA patient is said to meet genetic testing criteria after a trained clinical geneticist confirms there is an indication for genetic testing

ISSN: 1465-542X